ArticleBritish journal of pharmacology2021
Cannabigerolic acid, a major biosynthetic precursor molecule in cannabis, exhibits divergent effects on seizures in mouse models of epilepsy.
Article in British journal of pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.
- Innovations in Cannabis Delivery Systems: A Patent Review (2012-2024).Mini reviews in medicinal chemistry · 2025Pooled it
- Pharmacological Switching in Minor Phytocannabinoids: A Mechanistic Framework for Compound-Indication Matching and Precision Neurotherapeutic Development.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Calcium signaling in human and mouse microglia exhibit differential susceptibility to phytocannabinoids.Cell communication and signaling : CCS · 2026Article
- The impact of predator stress on electroshock seizure threshold: insights into GABAergic, glutamatergic, and serotonergic pathways in mice.Behavioral and brain functions : BBF · 2026Article
- Antiseizure Effects of Cannabidiol in Combination With Cannabigerol in the Maximal Electroshock Seizure Model.Basic & clinical pharmacology & toxicology · 2026Article
- Navigating dose-effect complexities and challenges in cannabinoid therapy for aging-related neurobiological changes.Frontiers in pharmacology · 2026Review
- The Pharmacological Profile of Plant-Derived Cannabinoids In Vitro.Current topics in behavioral neurosciences · 2026Review
- Physiological effect and pharmacokinetic evaluation of combined oral administration of cannabidiolic acid and cannabigerolic acid in dogs.Frontiers in veterinary science · 2026Article
- Traditional Chinese medicine on epilepsy: focus on N-methyl-D-aspartate receptors and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.Medical review (2021) · 2025Review
- Dysregulation of the Cannabinoid System in Childhood Epilepsy: From Mechanisms to Therapy.International journal of molecular sciences · 2025Review
- Assessing the adaptive role of cannabidivarinic acid (CBDVA) in aphid defense in Cannabis sativa.Journal of cannabis research · 2025Article
- Use of Medicinal Cannabis for Epilepsy in the Australian Community 2023-2024: A Cross-Sectional Survey.Journal of epilepsy research · 2025Article
- Minor Cannabinoid Profile of Unregulated Cannabidiol Products.Cannabis and cannabinoid research · 2025Article
- Pharmacokinetics of Non-Psychotropic Phytocannabinoids.Pharmaceutics · 2025Review
- A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Cannabigerol Treatment Shows Antiproliferative Activity and Causes Apoptosis of Human Colorectal Cancer Cells.Journal of pharmacopuncture · 2024Article
- Cannabinoids and healthy ageing: the potential for extending healthspan and lifespan in preclinical models with an emphasis on Caenorhabditis elegans.GeroScience · 2024Review
- Unveiling the Potential of Phytocannabinoids: Exploring Marijuana's Lesser-Known Constituents for Neurological Disorders.Biomolecules · 2024Review
- Cannabinoids and Genetic Epilepsy Models: A Review with Focus on CDKL5 Deficiency Disorder.International journal of molecular sciences · 2024Review
- Enhancing the action of serotonin by three different mechanisms prevents spontaneous seizure-induced mortality in Dravet mice.Epilepsia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 2 countries.
Funding
Abstract
background and purposeCannabis has been used to treat epilepsy for millennia, with such use validated by regulatory approval of cannabidiol (CBD) for Dravet syndrome. Unregulated artisanal cannabis-based products used to treat children with intractable epilepsies often contain relatively low doses of CBD but are enriched in other phytocannabinoids. This raises the possibility that other cannabis constituents might have anticonvulsant properties. EXPERIMENTAL APPROACH: We used the Scn1a KEY
resultsThe initial screen identified three phytocannabinoids with novel anticonvulsant properties: CBGA, cannabidivarinic acid (CBDVA) and cannabigerovarinic acid (CBGVA). CBGA was most potent and potentiated the anticonvulsant effects of clobazam against hyperthermia-induced and spontaneous seizures, and was anticonvulsant in the MES threshold test. However, CBGA was proconvulsant in the 6-Hz threshold test and a high dose increased spontaneous seizure frequency in Scn1a CONCLUSION AND IMPLICATIONS: These results suggest that CBGA, CBDVA and CBGVA may contribute to the effects of cannabis-based products in childhood epilepsy. Although these phytocannabinoids have anticonvulsant potential and could be lead compounds for drug development programmes, several liabilities would need to be overcome before CBD is superseded by another in this class.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.